Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer

Trial Profile

Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Ethiodized oil (Primary)
  • Indications Liver cancer
  • Focus Biomarker; Diagnostic use
  • Most Recent Events

    • 21 Apr 2017 The primary end point has been changed from Measuring Lipiodol deposition in tumor to Tumor response by Response Evaluation Criteria in Solid Tumors (RECIST).
    • 21 Apr 2017 Planned End Date changed from 1 May 2015 to 1 Oct 2017.
    • 21 Apr 2017 Planned primary completion date changed from 1 May 2015 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top